Robinson Bradshaw

Month: September 2009

NCI’s New BRCA1 Test: Broader Utility and Another Challenge to Traditional Genetic Tests

Contributed by Allison Williams Dobson of the Center for Genomics and Society at the University of North Carolina at Chapel Hill. As reported last week by GenomeWeb, on September 21, 2009, a team led by Shyam Sharan from the National Cancer Institute (NCI) published the development of a new BRCA1 test based on mouse embryonic […]

Why the Errors of the Human Provenance Project Will Echo Beyond the U.K.’s Borders

ScienceInsider has posted several pieces this morning describing and critiquing the U.K. Border Agency’s Human Provenance pilot project: Scientists are greeting with surprise and dismay a project to use DNA and isotope analysis of tissue from asylum seekers to evaluate their nationality and help decide who can enter the United Kingdom. “Horrifying,” “naïve,” and “flawed” […]

David Clark Moves to Deerfield

David Clark has been a partner and good friend at Robinson, Bradshaw & Hinson, and he was instrumental in launching the Genomics Law Report. David is moving on, becoming a partner at Deerfield Management Company in New York. He plans to continue to contribute to the Genomics Law Report from time to time, and we […]

Prometheus and Medical Methods Patents

On September 16 the Federal Circuit decided a patent case called Prometheus Laboratories Inc. v. Mayo Collaborative Services (pdf). Prometheus sued Mayo for infringing two patents on a method of optimizing drug therapy for autoimmune diseases. The question in the case was whether the method met the patentable subject matter standard of section 101 of […]

The “Wrongful Life” Debate

As briefly mentioned in a prior post and discussed in a Connecticut opinion released last Friday, courts continue struggling to apply standard negligence principles in the context of genetic science, especially in the area of “wrongful life.” In a typical wrongful life case, a physician or geneticist fails to diagnose a severe genetic problem in […]

What Happens if a DTC Genomics Company Goes Belly Up?

The following post was originally published in three parts on September 14, 15 and 16 in Genetic Future. Direct-to-consumer (DTC) genomics companies are not immune to the current recession. When TruGenetics, a new player in the DTC genomics space, announced in June that it would be handing out 10,000 free genome scans, both Genetic Future […]

23andMe to Offer Discounts to Docs, But at What Cost?

Mark Henderson of the Times of London recently sat down to talk with Anne Wojcicki, now the sole remaining co-founder of DTC genomics company 23andMe, to discuss the company’s future plans. As Mark wrote in yesterday’s paper, Wojcicki and 23andMe are undertaking what appears to be a new strategy for the company, encouraging “doctors to […]

What Happens When a Personal Genomics Company Goes Bankrupt

The first and second installments of a three-part series of guest posts by GLR contributors Daniel Vorhaus and Lawrence Moore are up today at Daniel MacArthur’s excellent Genetic Future blog. In this series, we consider what would happen to all of the personal information provided by customers of a personal genomics company if the company […]

ACLU Moves for Summary Judgment in Myriad Patent Case

In prior posts we’ve described the ACLU’s lawsuit challenging Myriad Genetic’s patents on BRCA1 and 2, the breast cancer susceptibility genes, and responded to readers’ questions about the effect of those patents on research. In the latest development in the case, the ACLU has filed a motion for summary judgment (the motion was filed on […]

CSHL and a Brief Survey on Genetic Testing for Psychiatric Diseases

As many readers are probably aware, Cold Spring Harbor Laboratory is presenting its second meeting on Personal Genomes next week. Freelance science writer and blogger Ginny Hughes will be speaking about the science and attitudes of genetic testing for psychiatric diseases. She’s prepared a very short survey on the topic so please help her out with a […]